Skip to main content

Prevalence of herpesvirus DNA in MS patients and healthy blood donors

Buy Article:

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.


Objectives – The aim of this study is to determine the DNA prevalence of different members of Herpesviridae in multiple sclerosis (MS) patients and to describe the possible effect of β-interferon treatment on such prevalence. Material and methods – With a nested polymerase chain reaction (PCR) assay we have studied the DNA of the peripheral blood mononuclear cells (PBMCs) of 204 whole blood samples, [102 from patients with relapsing-remitting MS (RRMS), of which 62 were treated with β-interferon, and 102 from healthy blood donors]. Results – We only found a statistically significant difference for human herpesvirus type 6 (HHV-6) DNA prevalence (P < 0.0001): HHV-6 is 2.26 times more frequent in MS patients than in healthy donors. There was no difference in the HHV-6 prevalence between β-interferon treated and untreated patients. Conclusion – 1. Among the herpesviruses, HHV-6 was the only one showing altered prevalence. This either indicates that HHV-6 is involved in the pathogenesis of MS, or it simply indicates that MS influences latency or reactivation of HHV-6 without any direct involvement of HHV-6 in the disease process of MS. 2. Treatment with β-interferon does not make a difference on the DNA prevalence of the herpesviruses studied in our MS patients.

Keywords: -interferon; HHV-6; multiple sclerosis; nested PCR

Document Type: Original Article

Affiliations: 1: Clinical Microbiology Service, Hospital Clínico San Carlos, Madrid, Spain, 2: Neurology Service, Hospital Clínico San Carlos, Madrid, Spain, 3: Neurology Service, Hospital Clínico San Carlos, Madrid, Spain

Publication date: 2002-02-01

  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more